Although eculizumab is only approved by the FDA to treat 3 rare indications, the high and increasing net sales for the drug have raised concerns about off-label use, according to a research letter in JAMA Internal Medicine.
Although eculizumab is only approved by the FDA to treat 3 rare indications, the high and increasing net sales for the drug have raised concerns about off-label use, according to a research letter in JAMA Internal Medicine. Past research from America’s Health Insurance Plans had found that revenues for orphan drugs “primarily come from their non-orphan and off-label use.”
When the drug was first approved in 2007 to treat paroxysmal nocturnal hemoglobinuria (PNH), eculizumab was the costliest drug in the world with a $400,000 per year price tag. The monoclonal antibody has since been approved for atypical hemolytic uremic syndrome and refractory generalized myasthenia. All 3 indications are for rare diseases and eculizumab was granted orphan designation by the FDA for each indication.
Since 2007, worldwide net sales for the drug have increased from $66 million to more than $3.5 billion in 2018, raising the question of whether the drug was being used off-label for non—FDA-approved indications. In addition to identifying off-label use, the researchers were trying to ascertain the evidence that would support such use.
The researchers from Oregon Health and Science University searched the keyword “eculizumab” on ClinicalTrials.gov, Google Scholar, and PubMed to identify clinical trials and noninvestigational studies. They extracted data on the size of the study, type of study, data of study, and clinical indication of the drug.
A total of 322 publications were included and most had more than 50 patients (77%). The studies used eculizumab for 39 distinct indications and only PNH and myasthenia gravis had confirmatory trials. For nearly all indications, there were no randomized controlled trials in the literature.
The authors suggested that future research should try to quantify how much of eculizumab’s annual revenue is tied to off-label use versus use for FDA-approved indications.
“…patients and clinicians should be aware that the evidence supporting off-label use consists mostly of case series/case reports, along with small observational and interventional studies,” the authors wrote.
Reference
Kim MS, Prasad V. The clinical trials portfolio for on-label and off-label studies of eculizumab [published online October 28, 2019]. JAMA Intern Med. doi:10.1001/jamainternmed.2019.4694.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More